Agilent Technologies Inc A reported Q1 FY22 revenues rose 8% Y/Y to $1.67 billion, beating analysts average estimate of $1.46 billion.
- The firm said core revenues, which exclude the impact of currency and acquisitions and divestitures over the last 12 months, grew 9%.
- Agilent said that revenues for its diagnostics and genomic group rose 15% Y/Y to $339.0 million.
- Revenues for its life sciences and applied markets group rose 6% to $976.0 million, and revenues for the Agilent Crosslab Group grew 8% to $359.0 million.
- Agilent reported a net income of $368 million, or $1.21 per share, compared to $328 million, or $1.06 in Q1 2021, beating analysts' average estimate of $1.03.
- Guidance: For Q2 FY22, Agilent expects revenues of $1.59 billion - $1.62 billion and adjusted EPS of $1.10 - $1.12.
- Analysts expected Q2 revenues of $1.44 billion and EPS of $0.99.
- For FY22, the Company raised its revenue guidance to $6.67 billion - $6.73 billion, representing a growth of 5.6% - 6.5% and core revenues growth of 7% - 8%, versus the consensus of $6.34 billion.
- The Company's forecast adjusted EPS of $4.80 - $4.90, compared to the analysts' estimate of $4.70.
- Price Action: A shares are down 0.80% at $129.44 during the market session on the last check Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in